Evaluation of improvement effects of angiotensin II receptor blockers on glycemic and lipid metabolism in renal transplant patients
- Conditions
- Stable hypertensive patient who is administering ARB after renal transplant
- Registration Number
- JPRN-UMIN000003206
- Lead Sponsor
- Department of Surgery and Oncology Graduate School of Medical Sciences Kyushu University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 46
Not provided
1.Ptient with graft loss 2.Patient who has a history of hypersensitivity 3.Patient who is pregnant or a female patient who is expecting to become pregnant 4.Patient with extremely bad secretion of bile (total bilirubin: >= 2.0 mg/dL) 5.Patient who has serious hepatic disorder (GOT or GPT: >= 100 IU/L) 6.Patient who has serious renal disorder (serum creatinine: >= 3.0 mg/dL) 7.Patient with hyperkalemia (K: >= 5.5 mEq/L) 8.Patient who is currently receiving pioglitazone 9.Patient who is currently receiving angiotensin converting enzyme inhibitor 10.Patient who is currently receiving lipid-lowering therapy with fibrate agent 11.Patient who began taking statin within two months before start of the study 12.Patient with whom the physician-in-charge considered inappropriate as a subject of the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes in serum triglyceride level and adiponectin level from baseline to 12 weeks after
- Secondary Outcome Measures
Name Time Method Casual blood pressure, fasting blood glucose, HbA1c, glycoalbumin, fasting insulin, HOMA-IR (calculation from blood glucose level and insulin level), LDL-C, HDL-C, serum creatinine, eGFR (calculation from serum creatinine level), urinary albumin-to-creatinine ratio, adverse event